Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ifenprodil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.87 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.87 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.87 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.87 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.87 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.87 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.87 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.87 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.87 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.87 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.62 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.87 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.87 |
| ▸ | HTR2B | P41595 | 4/20 | 0.87 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ifenprodil SCHEMBL364019 | 1.00 | GMNN (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL27730851 | 0.99 | GMNN (0.98) | GMNNPMP22NPSR1GAAGRIN2B | |
| (R,S)-Ifenprodil SCHEMBL12618846 | 0.93 | GRIN2B (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL34010 | 0.93 | GRIN2B (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL12496650 | 0.93 | GRIN2B (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| (R,S)-Ifenprodil SCHEMBL21614195 | 0.93 | GRIN2B (1.00) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL17654723 | 0.92 | GRIN2B (0.97) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL11159184 | 0.92 | GRIN2B (0.97) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL29237720 | 0.91 | GRIN2B (0.95) | GMNNPMP22NPSR1GAAGRIN2B | |
| Ifenprodil SCHEMBL26105078 | 0.90 | GRIN2B (0.85) | GMNNPMP22NPSR1GAAGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240391930-A1 | SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| EP-3443955-B1 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | PHARNEXT (FR) | 2021-06-16 | — | — | EP | disclosed |
| EP-3482753-B1 | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2021-01-27 | — | — | EP | disclosed |
| US-20200222409-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2020-07-16 | — | — | US | disclosed |
| US-10617689-B2 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | PHARNEXT (FR) | 2020-04-14 | — | — | US | disclosed |
| US-10596160-B2 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | PHARNEXT (FR) | 2020-03-24 | — | — | US | disclosed |
| US-20200085790-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2020-03-19 | — | — | US | disclosed |
| US-20140038927-A1 | COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2014-02-06 | — | — | US | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20130090307-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2013-04-11 | — | — | US | disclosed |
| US-20130085122-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2013-04-04 | — | — | US | disclosed |
| EP-2560631-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | Pharnext (FR) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012117076-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-0971712-A1 | COMPOSITIONS FOR THE INHIBITION OF BONE RESORPTION | Smith & Nephew plc (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998035674-A1 | COMPOSITIONS FOR THE INHIBITION OF BONE RESORPTION | SMITH & NEPHEW PLC (GB) | 1998-08-20 | — | — | WO | disclosed |
| EP-0432994-A2 | Excitatory amino acid antagonists as anti-emetic drugs | Olney, John William (US) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | ADRA1A 2357/4885ADRA2A 2641/4885HTR2A 3947/4885 |
| US-20240391930-A1 | SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, SGMS1, PMP22 | ADRA1A 2656/4885ADRA2A 2872/4885HTR2A 3992/4885 |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | ADRA1A 645/4885ADRA2A 535/4885HTR2A 70/4885 |
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, PMP22, NR1H2 | ADRA1A 2785/4885ADRA2A 2963/4885HTR2A 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.